Freedom Biosciences is a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics. Using its discovery platform, the company has identified potent chemical combinations to enhance the safety and therapeutic profiles of existing treatments. With a diverse portfolio of assets including programs with clinical data and multiple exploratory programs, Freedom Biosciences aims to revolutionize the treatment of mental health indications.
The company was co-founded in 2021 by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital, and Dina Burkitbayeva, a co-founder of PsyMed Ventures.
The company's recent milestone includes a Venture Round investment at 14 February 2023 from Manta Ray, Atacama Ventures, and LongeVC. This investment signifies a vote of confidence in Freedom Biosciences' vision and potential for driving innovation within the biotechnology space.
Industries: Biotechnology
